Studies On The Safety Of Recombinant Lactobacillus Plantarum Expressing Angiotensin Converting Enzyme Inhibitory Peptide

As is well known that hypertension is one of the major diseases which is endangering human health. at the same time, it is the most important risk factors in coronary heart disease, arteriosclerosis, heart and kidney failure. For now, we have developed a lot of new drug on the treatment of hypertension, but the biggest problem is that a side effect of these drugs is too large. Therefore, the development has anti hypertensive effects, side effects, safe and long-term use of biologically active substances become a popular research today. We using genetic engineering techniques to construct the antihypertensive effect of recombinant LactobacilIus and preliminary test results indicate that the antihypertensive effect was very obvious, and longer than the duration of normal blood pressure medicine. To ensure security. in accordance with the relevant national standards, we have evaluated the toxicological safety and drug resistance of the anti hypertensive peptides of genetic engineering recombinant Lactobacillus. to provide experimental data for further application of this strains.Content and results:1An acute toxicity test to determine the median lethal dose LD50test bacteria and the maximum tolerated dose MTI3, we found that the bacteria had no significant adverse effects on the signs of mice, all the physiological parameters, liver and kidney tissue not have side effects, autopsy no abnormal tissues and organs, and the measurement of the median lethal dose LD50values are non-toxic level, and provide a preliminary basis for the safe application of the bacteria.2Genetic toxicity of bone marrow micronucleus test is a screening fast and sensitive routine testin, and is the must to be done test to evaluate the toxicity of pesticides, drugs. food additives. Through bone narrow micronucleus, we found that the micronucleus rate of gap of antihypertensive peptide of recombinant genetic engineering lactobacillus and control group have no significant difference. Initial guess the test bacteria chromosome of the body’s integrity and chromosome segregation, the recombinant strain did not mutagenic effect.3Translocation test Intragastricaily four weeks mice to detect the weight of mice, grew well, test the expiration of the eve under sterile conditions, blood coated MRS solid tablet containing the erytltroniycin resistance, as vvell as weighing the spleen, kidneyand then ground to take a certain amount of homogenate coated board, did not find the test bacteria translocation phenomenon.4Controlled trials By blood pressure medicine captopril controlled trials and has been listed. detection of heart, liver and spleen and kidney organs, body weight changes, conventional indicators such as discover, test strains and blood pressure medicine captopril and blank control group and there is no significant difference, further proof of the experimental strain security.5Drug sensitivity test This test measured the bacteriostatic circle diameter of the test strains for recombinant antimicrobial resistance of bacteria to make a preliminary evaluation of revealed antihypertensive peptide in recombinant gene engineering lactobacillrIs on amoxicillin and chloramphenicol are highly sensitive, sensitive to penicillin and gentamicin, is not sensitive to erythromycin.(recombinant bacteria containing the erythromycin resistance gene).Description through a series of preliminary experiment for security evaluation of anti hypertensive peptide of recombinant genetic engineering lactobacillus of security, for further research and application of the bacteria providing a scientific basis.